A2 Vertaisarvioitu katsausartikkeli tieteellisessä lehdessä
Longitudinal biomarker studies in human neuroimaging: capturing biological change of Alzheimer’s pathology
Tekijät: Fischer, Larissa; Parker, Dana; Maboudian, Samira; Fonseca, Corrina; Tato-Fernández, Claudia; Annen, Lucie; Arunachalam, Prithvi; Bacci, Julia R.; Barboure, Michelle; Capelli, Serena; Karagianni, Stamatia; Collij, Lyduine E.; Edison, Paul; Fox, Nick C.; Franzmeier, Nicolai; Grothe, Michel J.; Jagust, William J.; Maass, Anne; Malpetti, Maura; Paterson, Ross W.; Sogorb-Esteve, Aitana; Schöll, Michael
Kustantaja: BioMed Central
Julkaisuvuosi: 2026
Lehti: Alzheimer's Research and Therapy
Artikkelin numero: 13
Vuosikerta: 18
eISSN: 1758-9193
DOI: https://doi.org/10.1186/s13195-025-01920-6
Julkaisun avoimuus kirjaamishetkellä: Avoimesti saatavilla
Julkaisukanavan avoimuus : Kokonaan avoin julkaisukanava
Verkko-osoite: https://doi.org/10.1186/s13195-025-01920-6
Rinnakkaistallenteen osoite: https://research.utu.fi/converis/portal/detail/Publication/505810761
Rinnakkaistallenteen lisenssi: CC BY
Rinnakkaistallennetun julkaisun versio: Kustantajan versio
Despite extensive research, open questions about the biological underpinnings of Alzheimer’s disease (AD) remain. Neuroimaging biomarkers based on positron emission tomography (PET) and magnetic resonance imaging (MRI) offer in vivo insights into these complex biological changes and interactions. However, most evidence to date comes from cross-sectional studies, limiting our understanding of disease progression. Longitudinal studies enable the investigation of biological changes within individuals, revealing how pathology evolves over time. With this review, we provide an overview of how longitudinal imaging biomarker studies have advanced the field and how they can contribute to future research. We highlight longitudinal biomarker studies that have provided critical insights into disease trajectories, staging, and individual variability. We further assess longitudinal multimodal studies which have elucidated interactions between AD-specific pathology, amyloid-β and tau, and broader biological changes like neurodegeneration, neuronal dysfunction, vascular disease, and inflammation. Further, we discuss associations of brain changes with symptomatology and clinical outcomes and conclude with challenges and future directions.
Ladattava julkaisu This is an electronic reprint of the original article. |  |
Julkaisussa olevat rahoitustiedot:
Open access funding provided by University of Gothenburg. This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors. Open access funding was provided by the University of Gothenburg.
